HeartCare Medical-B (06609.HK) Surges Over 12% on Expected FY2025 Pretax Profit of RMB 80 Million, Marking Return to Profitability

According to the Zhitong Finance APP, HeartCare-B (06609) surged over 12%. As of press time, it rose by 11.54%, trading at HK$56.55, with a turnover of HK$2.8647 million.

On the news front, HeartCare announced that the group expects to achieve revenue between approximately RMB 400 million and RMB 410 million for the fiscal year ending December 31, 2025, representing an increase of at least 43.9% year-over-year; pre-tax profit of approximately RMB 80 million, turning losses into profits year-over-year. The revenue growth is mainly due to the launch of new products and technologies for ischemic stroke and an increase in market share of ischemic stroke products; scaled commercialization of intracranial stents and increased sales of other hemorrhagic stroke products; continuous growth in the sales of interventional access products; and effective cost control measures in sales costs and administrative expenses, which have reduced the expense ratio.

In addition, HeartCare also announced that the registration application for the self-expanding intracranial drug-eluting stent developed by the group has been accepted by the National Medical Products Administration. The self-expanding intracranial drug-eluting stent is used for the treatment of intracranial atherosclerotic stenosis, providing support and opening for narrowed and obstructed lumens, and effectively preventing in-stent lumen restenosis. According to publicly available information, there are currently no similar products approved for marketing worldwide, and the company's R&D progress for this type of product is at a leading level within the industry.